There is a toxicity linked to the chronic use of nitrous oxide, leading to neurological disorders such as combined sclerosis of the spinal cord. One thus frequently observes patients presenting disorders of walking or paresthesias, of more or less resolving evolution being able to go until the need for using a wheelchair and more recently cases of thrombosis were reported Serum or urine N2O assays are rarely performed routinely, because they do not allow to ensure a real exposure due to the very short half-life of this gas in the body. Thus, other biological monitoring markers are mentioned in the literature, such as vitamin B12 or homocysteine. Unfortunately, there are still no recommendations for biological monitoring of nitrous oxide consumption. Moreover, underlying mechanisms leading to clinical outcomes remains misunderstood.
Study Type
OBSERVATIONAL
Enrollment
356
Biological analyses in the framework of care with conservation of blood samples
BETHUNE
Béthune, France
RECRUITINGBoulogne Sur Mer
Boulogne-sur-Mer, France
RECRUITINGCALAIS
Calais, France
RECRUITINGLens
Lens, France
RECRUITINGChu Lille
Lille, France
RECRUITINGNantes
Nantes, France
RECRUITINGRoubaix
Roubaix, France
RECRUITINGRouen
Rouen, France
RECRUITINGBlood markers related to nitrous oxide consumption
Biomarkers of cobalamin metabolism, methionine cycle and oxidative stress
Time frame: through study completion an average of 1 year
Blood markers related to nitrous oxide clinical outcomes.
Biomarkers of cobalamin metabolism, methionine cycle and oxidative stress and biological markers of neurological damage.
Time frame: Baseline, at 4 weeks, at 3 months and at 6 months
Estimated and self-reported nitrous oxide consumption
Time frame: Baseline, at 4 weeks,and/or at 3 months and at 6 months
The severity of the clinical signs related to nitrous oxide consumption.
The severity of the signs noted during the interrogation and consultation of the patients by filling out a pre-established form listing the neurological signs (gait disorders evaluated by the PND score, presence of paresthesia and associated clinical signs (thrombotic and psychiatric events)
Time frame: Baseline, at 4 weeks,and/or at 3 months and at 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.